Diagnostics

News and analysis on diagnostic technologies and applications.

Natera said that this research collaboration and others will help it clinically validate its circulating tumor DNA assay Signatera. 

Becton Dickinson and Euroclone aim to develop and commercialize the molecular assays for launch outside the US in 2018, and in the US at a later date.

The study is part of an effort to drive health plan coverage for Exosome's ExoDx Prostate IntelliScore prostate cancer test.

The alliance will combine the two firms' technologies and know-how to provide doctors with insights into patients' health status.

The company's PD-L1 IHC 28-8 pharmDx diagnostic can now be used in cases of urothelial carcinoma and squamous cell carcinoma of the head and neck.

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.